Tumor Targeting and Drug Delivery by Anthrax Toxin
AbstractAnthrax toxin is a potent tripartite protein toxin from Bacillus anthracis. It is one of the two virulence factors and causes the disease anthrax. The receptor-binding component of the toxin, protective antigen, needs to be cleaved by furin-like proteases to be activated and to deliver the enzymatic moieties lethal factor and edema factor to the cytosol of cells. Alteration of the protease cleavage site allows the activation of the toxin selectively in response to the presence of tumor-associated proteases. This initial idea of re-targeting anthrax toxin to tumor cells was further elaborated in recent years and resulted in the design of many modifications of anthrax toxin, which resulted in successful tumor therapy in animal models. These modifications include the combination of different toxin variants that require activation by two different tumor-associated proteases for increased specificity of toxin activation. The anthrax toxin system has proved to be a versatile system for drug delivery of several enzymatic moieties into cells. This highly efficient delivery system has recently been further modified by introducing ubiquitin as a cytosolic cleavage site into lethal factor fusion proteins. This review article describes the latest developments in this field of tumor targeting and drug delivery. View Full-Text
Share & Cite This Article
Bachran, C.; Leppla, S.H. Tumor Targeting and Drug Delivery by Anthrax Toxin. Toxins 2016, 8, 197.
Bachran C, Leppla SH. Tumor Targeting and Drug Delivery by Anthrax Toxin. Toxins. 2016; 8(7):197.Chicago/Turabian Style
Bachran, Christopher; Leppla, Stephen H. 2016. "Tumor Targeting and Drug Delivery by Anthrax Toxin." Toxins 8, no. 7: 197.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.